| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/26/2023 | 64.27% | Goldman Sachs | $22 → $32 | Maintains | Buy |
| 03/09/2023 | 2.67% | JP Morgan | $19 → $20 | Maintains | Overweight |
| 12/29/2021 | 74.54% | B of A Securities | $37 → $34 | Maintains | Buy |
| 04/01/2020 | 28.34% | B of A Securities | → $25 | Initiates Coverage On | → Buy |
| 03/11/2020 | 23.2% | JP Morgan | $22 → $24 | Maintains | Overweight |
| 12/06/2019 | -7.6% | Goldman Sachs | $16 → $18 | Upgrades | Neutral → Buy |
| 08/14/2019 | 79.67% | JMP Securities | $44 → $35 | Maintains | Market Outperform |
| 03/11/2019 | 33.47% | Barclays | → $26 | Initiates Coverage On | → Overweight |
| 12/12/2018 | 69.4% | Wedbush | $31 → $33 | Reiterates | Outperform → Outperform |
| 09/17/2018 | 125.87% | JMP Securities | $33 → $44 | Maintains | Market Outperform |
What is the target price for Kiniksa Pharmaceuticals (KNSA)?
The latest price target for Kiniksa Pharmaceuticals (NASDAQ: KNSA) was reported by Goldman Sachs on July 26, 2023. The analyst firm set a price target for $32.00 expecting KNSA to rise to within 12 months (a possible 64.27% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kiniksa Pharmaceuticals (KNSA)?
The latest analyst rating for Kiniksa Pharmaceuticals (NASDAQ: KNSA) was provided by Goldman Sachs, and Kiniksa Pharmaceuticals maintained their buy rating.
When is the next analyst rating going to be posted or updated for Kiniksa Pharmaceuticals (KNSA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiniksa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiniksa Pharmaceuticals was filed on July 26, 2023 so you should expect the next rating to be made available sometime around July 26, 2024.
Is the Analyst Rating Kiniksa Pharmaceuticals (KNSA) correct?
While ratings are subjective and will change, the latest Kiniksa Pharmaceuticals (KNSA) rating was a maintained with a price target of $22.00 to $32.00. The current price Kiniksa Pharmaceuticals (KNSA) is trading at is $19.48, which is out of the analyst's predicted range.